CN110237229A - A kind of pharmaceutical composition of mesotherapy and preparation method thereof for reducing skin pigment and treating pain degree - Google Patents
A kind of pharmaceutical composition of mesotherapy and preparation method thereof for reducing skin pigment and treating pain degree Download PDFInfo
- Publication number
- CN110237229A CN110237229A CN201910704274.1A CN201910704274A CN110237229A CN 110237229 A CN110237229 A CN 110237229A CN 201910704274 A CN201910704274 A CN 201910704274A CN 110237229 A CN110237229 A CN 110237229A
- Authority
- CN
- China
- Prior art keywords
- injection
- pharmaceutical composition
- vitamin
- mesotherapy
- skin pigment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 51
- 208000002193 Pain Diseases 0.000 title claims abstract description 30
- 230000036407 pain Effects 0.000 title claims abstract description 30
- 239000000049 pigment Substances 0.000 title claims abstract description 23
- 238000000694 mesotherapy Methods 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 44
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 32
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 22
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 22
- 108010024636 Glutathione Proteins 0.000 claims abstract description 21
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims abstract description 20
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 20
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 20
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 19
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 18
- 229960004393 lidocaine hydrochloride Drugs 0.000 claims abstract description 18
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 150000001413 amino acids Chemical class 0.000 claims abstract description 6
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 5
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 5
- 229940024606 amino acid Drugs 0.000 claims abstract description 3
- 229940090044 injection Drugs 0.000 claims description 104
- 239000007924 injection Substances 0.000 claims description 104
- 238000002347 injection Methods 0.000 claims description 104
- 239000000203 mixture Substances 0.000 claims description 22
- 229960003180 glutathione Drugs 0.000 claims description 14
- 239000008227 sterile water for injection Substances 0.000 claims description 14
- -1 Amino Acid Compound Chemical class 0.000 claims description 13
- 229940100226 tranexamic acid injection Drugs 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000005864 Sulphur Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 230000009467 reduction Effects 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 229960001407 sodium bicarbonate Drugs 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 35
- 229940079593 drug Drugs 0.000 description 21
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 16
- 238000006722 reduction reaction Methods 0.000 description 8
- 102000003425 Tyrosinase Human genes 0.000 description 7
- 108060008724 Tyrosinase Proteins 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 5
- 208000003351 Melanosis Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- 235000019158 vitamin B6 Nutrition 0.000 description 4
- 239000011726 vitamin B6 Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- HNNQYHFROJDYHQ-UHFFFAOYSA-N 3-(4-ethylcyclohexyl)propanoic acid 3-(3-ethylcyclopentyl)propanoic acid Chemical compound CCC1CCC(CCC(O)=O)C1.CCC1CCC(CCC(O)=O)CC1 HNNQYHFROJDYHQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003866 melanoblast Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000003859 smegma Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The embodiment of the invention discloses the pharmaceutical compositions of mesotherapy and preparation method thereof of a kind of reduction skin pigment and treatment pain degree, belong to technical field of pharmaceuticals.Described pharmaceutical composition includes following component: reduced glutathione, vitamin c, tranexamic acid, amino acid, vitamin b6, lipoic acid, lidocaine hydrochloride, sodium bicarbonate.It is confirmed by clinical test, pharmaceutical composition provided by the invention is used to reduce in the mesotherapy of skin pigment, and therapeutic effect is definite, and responding time is short, and can effectively mitigate treatment pain degree.
Description
Technical field
The present embodiments relate to technical field of pharmaceuticals, and in particular in a kind of reduction skin pigment and treatment pain degree
Pharmaceutical composition of mesotherapy and preparation method thereof.
Background technique
The melanoblast of the basal layer of epidermis secretes melanin, is prevented for resisting ultraviolet light under normal circumstances
Skin is encroached on by strong light.Intracorporal tyrosine and tyrosinase are in equilibrium state under normal circumstances, but strong when encountering ultraviolet light
When strong irradiation, the increase of sex hormone, melanocyte proliferation, melanocyte activity increases, and tyrosinase activity improves, black
Situations such as element synthesis increases, and tyrosinase activity improves, and leads to cutaneous pigmentation, sunburn, obscure skin generation.
The method of common reduction skin pigment includes: at present
1, using epidermis external application or oral whitening and freckle-removing product, epidermis externally applied product because the reason of skin barrier,
Drug can not reach skin corium, cannot play drug effect.In view of pharmacokinetics, drug metabolism and poisonous side effect of medicine are taken orally
Product equally has various drawbacks.
2, tartaric acid nti-freckle strips off epidermis using high concentration tartaric acid, reaches shining skin purpose, but process has feeling of pain, groups of people
Can also be with decortication, stammerer the phenomenon that, after treatment if sun-proof not in place, skin is easier obscure long color spot.
3, skin can be concentrated and be penetrated to laser/intense pulsed light nti-freckle using laser/intense pulsed light that instrument is emitted, right
The pigment at spot position is irradiated, and pigmented spots can be crashed to pieces and are metabolized under powerful laser irradiation, to reduce color spot.Swash
Situations such as light or intense pulsed light nti-freckle misoperation can cause skin burn, scar, depigmentation and blister, it is also possible to damage view
Nethike embrane, serious person can also blind.Skin injury needs certain time to restore after laser/intensive pulsed light, needs stringent sun-proof 3
A month or more, if maintenance and it is sun-proof it is improper easily cause more serious pigmentation, it is brighter than protochrome spot disease
It is aobvious.
Mesoderm (mesoderm) is between epidermis and skin corium.Mesotherapy is exactly to pass through drug as its name suggests
Specific device is delivered to a kind of mesoblastic mode, and in nineteen fifty-two, by Charles Robert Richet Mike skin, this first chief executive of Special Administrative Region is first proposed, can be from root
Color spot, skin acne, jaundice, dark and gloomy, the skin problems such as cutis laxa are solved on this.
At present in clinical treatment of the mesotherapy to reduce skin pigment, it is often used vitamin c and is treated, but pain
Spend high, many patients can not adhere to treating because in great pain, and curative effect is poor in clinical application for existing drug, work
It is slightly slow, therefore the pharmaceutical composition for developing the mesotherapy that can be effectively reduced skin pigment and treat pain degree has weight
The meaning wanted.
Summary of the invention
For this purpose, the embodiment of the present invention provides the medicine group of a kind of reduction skin pigment and the mesotherapy for treating pain degree
Object and preparation method thereof is closed, the pharmaceutical composition is curative for effect in the mesoderm treatment of skin pigment reduction, and pain is small,
It can obviously improve treatment pain degree.
To achieve the goals above, the embodiment of the present invention provides the following technical solutions:
According to a first aspect of the embodiments of the present invention, the embodiment of the invention provides a kind of reduction skin pigment and treatment pains
The pharmaceutical composition of the mesotherapy of pain degree, described pharmaceutical composition include following component: reduced glutathione, vitamin
C, tranexamic acid, amino acid, vitamin b6, lipoic acid, lidocaine hydrochloride, sodium bicarbonate.
Further, described pharmaceutical composition is by following content at being grouped as: glutathione for injection 0.01-
0.015g, vitamin c injection 0.06-0.1ml, tranexamic acid injection 0.08-0.12ml, Amino Acid Compound Injection
(18AA) 0.03-0.07ml, vitamin b6 injection 0.01-0.03ml, lipoic acid injection 0.48-0.52ml, hydrochloric acid benefit
Cacaine injection 0.18-0.22ml, sodium bicarbonate injection 0.4-0.7ml, sterilized water for injection 1-2ml.
Further, described pharmaceutical composition is by following content at being grouped as: glutathione for injection
0.012g, vitamin c injection 0.08ml, tranexamic acid injection 0.1ml, Amino Acid Compound Injection (18AA) 0.05ml,
Vitamin b6 injection 0.02ml, lipoic acid injection 0.5ml, lidocaine hydrochloride injection 0.2ml, sodium bicarbonate injection
0.53ml, sterilized water for injection 1.52ml.
According to a second aspect of the embodiments of the present invention, the embodiment of the invention provides a kind of reduction skin pigment and treatment pains
The preparation method of the pharmaceutical composition of the mesotherapy of pain degree, the described method comprises the following steps:
1) by glutathione for injection 0.01-0.015g, vitamin c injection 0.06-0.1ml, compound amino
Acid injection (18AA) 0.03-0.07ml, vitamin b6 injection 0.01-0.03ml, lidocaine hydrochloride injection 0.18-
It is spare that 0.22ml obtains mixture A after mixing；Lipoic acid injection 0.48-0.52ml and sodium bicarbonate injection 0.4-0.7ml
It is spare that mixture B is obtained after mixing；Tranexamic acid injection 0.08-0.12ml and sterilized water for injection 1-2ml is obtained after mixing
Mixture C is spare；
2) the mixture A, mixture B and mixture C are mixed.
Further, the pH value of described pharmaceutical composition is 6.9-7.1.
The effect of each ingredient is described below in the embodiment of the present invention:
Vitamin c: having reproducibility, can make melanin that reduction reaction occur, be reduced into from black colourless.
Reduced glutathione: being a kind of peptide of small molecule, be largely present in organism, mainly have protect liver, it is anti-oxidant,
The effects of removing interior free yl.Reduced glutathione has anti-oxidant, blocking melanin, inhibits tyrosinase activity, restores
The effects of melanin.
Lipoic acid: there is excellent reproducibility, melanin can be restored, while the production of free radical in skin can also be inhibited
It is raw, so that the excessive of melanin in skin fundamentally be inhibited to generate.
Tranexamic acid: it is similar to the substrate tyrosine structure of tyrosinase, can with the activity of Reverse transcriptase tyrosinase,
Influence the formation of melanin.
Vitamin b6 can reduce smegma, and amino acid can provide nutrition to skin to promote collagen raw
At so as to improve skin quality and oxidation caused by reducing fat secretion excessively is obscure.
Lidocaine hydrochloride: the effect primarily served is the effect for anesthesia.
Sodium bicarbonate: for adjusting the pH value of the pharmaceutical composition of mixture.
Sterilized water for injection: for diluting the concentration of drug.
In each ingredient of pharmaceutical composition of the embodiment of the present invention, including the lower drug of pH value, such as injection reduced form paddy Guang
Sweet peptide, vitamin c injection, Amino Acid Compound Injection (18AA), vitamin b6 injection, lidocaine hydrochloride injection；
PH value higher drug, such as lipoic acid injection, sodium bicarbonate injection；PH value is injected close to neutral drug, such as tranexamic acid
Liquid.The study found that can effectively reduce the pain degree for the treatment of when the pH value of mixed pharmaceutical composition is close to 7.Work as pH value
When variation, the activity of drug can be gradually decreased, in order to inhibit the active reduction of final drug, using first individually mixing respectively obtains
Close to neutral drug, then mixing above-mentioned three kinds of drugs be can be used for the lower drug of pH value, pH value higher drug and pH value.
The embodiment of the present invention has the advantages that
The pharmaceutical composition of the embodiment of the present invention is using reduced glutathione, vitamin c and lipoic acid as reducing agent, three
Synergistic effect is played, melanin intermediates can be preferably restored, block the formation of melanin.Reduced glutathione and ammonia first
Naphthenic acid can inhibit the synthesis of tyrosinase, reduce the generation of melanin.Amino acid and vitamin b6 can improve skin quality
And the secretion of grease is reduced, it is obscure with the oxidation for reducing grease.The above substance shares, and can effectively mitigate skin pigment.It adjusts
The tingling sensation for saving the pH value of pharmaceutical composition and lidocaine hydrochloride being added when can effectively reduce injection, and used in dilution
Sterilized water for injection without ion concentration reduces unnecessary ion concentration.By adjusting the additive amount of sodium bicarbonate injection
With the pH of regulating medicine composition.It is confirmed by clinical test, pharmaceutical composition provided by the invention is for reducing skin pigment
Mesotherapy in, therapeutic effect is definite, and responding time is short, and can effectively mitigate treatment pain degree.
Specific embodiment
Embodiments of the present invention are illustrated by particular specific embodiment below, those skilled in the art can be by this explanation
Content disclosed by book is understood other advantages and efficacy of the present invention easily, it is clear that described embodiment is the present invention one
Section Example, instead of all the embodiments.Based on the embodiments of the present invention, those of ordinary skill in the art are not doing
Every other embodiment obtained under the premise of creative work out, shall fall within the protection scope of the present invention.
Glutathione for injection specification 1.0g is purchased from Fuan medicine company group Hubei (state, people pharmaceutical Co. Ltd
The quasi- word H20183086 of medicine).Vitamin c injection specification 2ml:0.25g is purchased from He'nan Runhong Pharmaceutical Co., Ltd.'s (traditional Chinese medicines
Quasi- word H20043104).Tranexamic acid injection specification 5ml:0.5g*5 branch is purchased from Fuzhou Neptunus Fuyao Pharmaceuticals Co., Ltd.
(national drug standard H20059504).250ml:12.5g/ bottles of Amino Acid Compound Injection (18AA) specification is purchased from the pharmacy of Yichang Three Gorges
Co., Ltd (national drug standard H19993921).Vitamin b6 injection specification 50mg:1ml*10 branch is breathed out gloomy purchased from Shanghai modern
(Shangqiu) pharmaceutcal corporation, Ltd (national drug standard H41021938).Lipoic acid injection specification 12ml:0.3g*5 branch is purchased from Dandong
Yi Chuan medicine company Co., Ltd (national drug standard H20065201).Sodium bicarbonate injection specification 10ml:0.5g is purchased from Hebei
It is at medicine company limited liability company (national drug standard H13022134).Lidocaine hydrochloride injection specification 5ml:0.1g*5 branch, purchase
From Hebei Tiancheng Pharmaceutical Co., Ltd. (national drug standard H13022313).Sterilized water for injection specification 500ml is purchased from Sichuan
Cologne medicine company limited liability company (national drug standard H20044405).
Embodiment 1
The pharmaceutical composition of the present embodiment is by following content at being grouped as: glutathione for injection 0.012g,
Vitamin c injection 0.06ml, tranexamic acid injection 0.11ml, Amino Acid Compound Injection (18AA) 0.07ml, vitamin
B6 injection 0.01ml, lipoic acid injection 0.48ml, lidocaine hydrochloride injection 0.2ml, sodium bicarbonate injection
0.52ml, sterilized water for injection 1.63ml.
The preparation method of the pharmaceutical composition of the present embodiment:
1) mixture A: by glutathione for injection, vitamin c injection, Amino Acid Compound Injection
(18AA), vitamin b6 injection, lidocaine hydrochloride injection mixing；Mixture B: by lipoic acid injection and sodium bicarbonate
Injection mixing；Mixture C: tranexamic acid injection and sterilized water for injection mixing；
2) said mixture A, mixture B and mixture C are mixed.
The pH value of pharmaceutical composition made from the present embodiment is 6.94.
Embodiment 2
The pharmaceutical composition of the present embodiment is by following content at being grouped as: glutathione for injection 0.012g,
Vitamin c injection 0.08ml, tranexamic acid injection 0.1ml, Amino Acid Compound Injection (18AA) 0.05ml, vitamin
B6 injection 0.02ml, lipoic acid injection 0.5ml, lidocaine hydrochloride injection 0.2ml, sodium bicarbonate injection
0.53ml, sterilized water for injection 1.52ml.
The preparation method is the same as that of Example 1 for the pharmaceutical composition of the present embodiment.The pH of pharmaceutical composition made from the present embodiment
Value is 7.02.
Embodiment 3
The pharmaceutical composition of the present embodiment is by following content at being grouped as: glutathione for injection 0.01g,
Vitamin c injection 0.08ml, tranexamic acid injection 0.12ml, Amino Acid Compound Injection (18AA) 0.07ml, vitamin
B6 injection 0.01ml, lipoic acid injection 0.52ml, lidocaine hydrochloride injection 0.2ml, sodium bicarbonate injection
0.58ml, sterilized water for injection 1.42ml.
The preparation method is the same as that of Example 1 for the pharmaceutical composition of the present embodiment.The pH of pharmaceutical composition made from the present embodiment
Value is 7.07.
Embodiment 4
The pharmaceutical composition of the present embodiment is by following content at being grouped as: glutathione for injection 0.015g,
Vitamin c injection 0.06ml, tranexamic acid injection 0.08ml, Amino Acid Compound Injection (18AA) 0.04ml, vitamin
B6 injection 0.03ml, lipoic acid injection 0.48ml, lidocaine hydrochloride injection 0.22ml, sodium bicarbonate injection
0.56ml, sterilized water for injection 1.53ml.
The preparation method is the same as that of Example 1 for the pharmaceutical composition of the present embodiment.The pH of pharmaceutical composition made from the present embodiment
Value is 7.1.
Embodiment 5
The pharmaceutical composition of the present embodiment is by following content at being grouped as: glutathione for injection 0.01g, dimension
Raw element c injection 0.1ml, tranexamic acid injection 0.11ml, Amino Acid Compound Injection (18AA) 0.03ml, vitamin b6
Injection 0.02ml, lipoic acid injection 0.52ml, lidocaine hydrochloride injection 0.18ml, sodium bicarbonate injection
0.61ml, sterilized water for injection 1.43ml.
The preparation method is the same as that of Example 1 for the pharmaceutical composition of the present embodiment.The pH of pharmaceutical composition made from the present embodiment
Value is 6.95.
Comparative example 1
The pharmaceutical composition of this comparative example the difference from embodiment 1 is that, lipoic acid is substituted for the glutathione of equivalent,
The additive amount for adjusting sodium bicarbonate injection simultaneously makes the pH value 6.9-7.1 of pharmaceutical composition obtained.
Comparative example 2
The pharmaceutical composition of this comparative example the difference from embodiment 1 is that, lipoic acid is substituted for the vitamin c of equivalent,
The additive amount for adjusting sodium bicarbonate injection simultaneously makes the pH value 6.9-7.1 of pharmaceutical composition obtained.
Comparative example 3
The pharmaceutical composition of this comparative example and the difference of embodiment 1 are only that, do not include sodium bicarbonate injection.
Effect example
Human efficiency's evaluation
1 general information
Select 160 patients as subjects, wherein skin colour is compared with 55 deep, skin is 38 obscure, skin-color
It 42, plain spot and is reduced skin pigment demand 25, is divided into observation 1-5 group and control 1-3 group by random method, every group each
20.Each group patient clinical data no significant difference (P > 0.05), is comparable.This research is entrusted through hospital's ethics
Member can ratify, and patient or family members know and sign letter of consent.
Exclusion criteria: skin severe infections patient；Serious sensitivity skin patient；Corticosteroid dermatitis patient；To in formula
Drug has autopath；Pregnant and lying-in women；Mental disorder patient；Cardiovascular and cerebrovascular, liver, kidney serious disease patient.
2 treatment methods
Cleaning face, cleans up, iodophor disinfection 2 times after applying lidocaine emulsifiable paste 30min, and 75% alcohol takes off iodine 1 time.
32g syringe needle injects the composition into patient's skin corium, observe 1-5 group and compare 1-3 group patient be respectively adopted embodiment 1-5 and
Pharmaceutical composition made from comparative example 1-3 (current existing system).Depth of needle 1.2mm-1.5mm.Full-face co-injection 3ml.It is postoperative
At once it is applied on the surface 20 minutes using 4 DEG C of tool font size medical aseptic facial masks, keeps facial cleansing sterile in 24 hours after injection.
3 observation index
Skin colour improvement is divided into Pyatyi: be obviously improved, it is more apparent improves, be not improved, it is more apparent deteriorate, obvious evil
Change.
Pain degree is divided into Pyatyi: painless, mild pain sense, moderate pain sense, relatively pain but still endure, can not
The pain endured.
4 results
Postoperative 7 days-postoperative 30 days return visit patients of immediate postoperative-.The improvement of each group skin colour the results are shown in Table 1.
Table 1
| Group | It is obviously improved (people) | More apparent improvement (people) | It is not improved (people) | Responding time (day) |
| Observe 1 group | 14 | 6 | 0 | 8.6±0.5 |
| Observe 2 groups | 16 | 4 | 0 | 8.0±0.3 |
| Observe 3 groups | 15 | 5 | 0 | 8.4±0.3 |
| Observe 4 groups | 14 | 6 | 0 | 8.8±0.4 |
| Observe 5 groups | 14 | 6 | 0 | 8.5±0.6 |
| Compare 1 group | 5 | 12 | 2 | 13.7±1.1 |
| Compare 2 groups | 3 | 15 | 2 | 14.5±0.9 |
| Compare 3 groups | 9 | 11 | 0 | 10.1±0.6 |
As shown in Table 1, it observes and is obviously improved number significantly more than control 1-3 group in 1-5 group, responding time shorter than control 1-
3 groups, illustrate that the pharmaceutical composition of the embodiment of the present invention is better than control 1-3 group to the therapeutic effect for reducing skin pigment, and see
It is short to imitate the time.
The improvement of each group treatment pain the results are shown in Table 2.
Table 2
As shown in Table 2, it observes painless number in 1-5 group and is significantly more than control 1-3 group, illustrate the embodiment of the present invention
Pharmaceutical composition is better than control 1-3 group to the effect for the improvement treatment pain for reducing skin pigment.
Although above having used general explanation and specific embodiment, the present invention is described in detail, at this
On the basis of invention, it can be made some modifications or improvements, this will be apparent to those skilled in the art.Therefore,
These modifications or improvements without departing from theon the basis of the spirit of the present invention are fallen within the scope of the claimed invention.
Claims (5)
1. a kind of pharmaceutical composition for the mesotherapy for reducing skin pigment and treating pain degree, which is characterized in that the medicine
Compositions include following component: reduced glutathione, vitamin c, tranexamic acid, amino acid, vitamin b6, sulphur are pungent
Acid, lidocaine hydrochloride, sodium bicarbonate.
2. the pharmaceutical composition of the mesotherapy according to claim 1 for reducing skin pigment and treating pain degree,
It is characterized in that, described pharmaceutical composition is by following content at being grouped as: glutathione for injection 0.01-0.015g,
Vitamin c injection 0.06-0.1ml, tranexamic acid injection 0.08-0.12ml, Amino Acid Compound Injection (18AA) 0.03-
0.07ml, vitamin b6 injection 0.01-0.03ml, lipoic acid injection 0.48-0.52ml, lidocaine hydrochloride injection
0.18-0.22ml, sodium bicarbonate injection 0.4-0.7ml, sterilized water for injection 1-2ml.
3. the pharmaceutical composition of the mesotherapy according to claim 2 for reducing skin pigment and treating pain degree,
It is characterized in that, described pharmaceutical composition is by following content at being grouped as: glutathione for injection 0.012g, vitamin
C injection 0.08ml, tranexamic acid injection 0.1ml, Amino Acid Compound Injection (18AA) 0.05ml, vitamin b6 injection
0.02ml, lipoic acid injection 0.5ml, lidocaine hydrochloride injection 0.2ml, sodium bicarbonate injection 0.53ml, sterilizing note
It penetrates with water 1.52ml.
4. a kind of preparation method of the pharmaceutical composition for the mesotherapy for reducing skin pigment and treating pain degree, feature exist
In the described method comprises the following steps:
1) glutathione for injection 0.01-0.015g, vitamin c injection 0.06-0.1ml, amino acid are infused
Penetrate liquid (18AA) 0.03-0.07ml, vitamin b6 injection 0.01-0.03ml, lidocaine hydrochloride injection 0.18-0.22ml
It is spare that mixture A is obtained after mixing；After lipoic acid injection 0.48-0.52ml and sodium bicarbonate injection 0.4-0.7ml is mixed
It is spare to obtain mixture B；Tranexamic acid injection 0.08-0.12ml and sterilized water for injection 1-2ml obtains mixture C after mixing
It is spare；
2) the mixture A, mixture B and mixture C are mixed.
5. the system of the pharmaceutical composition of the mesotherapy according to claim 4 for reducing skin pigment and treating pain degree
Preparation Method, which is characterized in that the pH value of described pharmaceutical composition is 6.9-7.1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910704274.1A CN110237229A (en) | 2019-07-31 | 2019-07-31 | A kind of pharmaceutical composition of mesotherapy and preparation method thereof for reducing skin pigment and treating pain degree |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910704274.1A CN110237229A (en) | 2019-07-31 | 2019-07-31 | A kind of pharmaceutical composition of mesotherapy and preparation method thereof for reducing skin pigment and treating pain degree |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110237229A true CN110237229A (en) | 2019-09-17 |
Family
ID=67893907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910704274.1A Pending CN110237229A (en) | 2019-07-31 | 2019-07-31 | A kind of pharmaceutical composition of mesotherapy and preparation method thereof for reducing skin pigment and treating pain degree |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110237229A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112386520A (en) * | 2020-11-24 | 2021-02-23 | 西安润玉医疗科技有限公司 | Mesoderm injection composition for comprehensively improving skin color and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060216251A1 (en) * | 2005-03-24 | 2006-09-28 | Tracie Martyn International, Llc | Topical formulations and methods of use |
| CN101125126A (en) * | 2006-08-16 | 2008-02-20 | 丛繁滋 | Method for preparing medical freeze-dried powder (injection) preparation |
| JP2010111590A (en) * | 2008-11-04 | 2010-05-20 | Oriza Yuka Kk | Melanogenesis inhibitor |
| US20150342854A1 (en) * | 2012-12-27 | 2015-12-03 | Hayashibara Co., Ltd. | External dermal composition for anti-ageing and method for producing the same |
| CN105535025A (en) * | 2016-01-14 | 2016-05-04 | 无锡瑞博美容咨询服务有限公司 | Skin tendering and whitening nutrient solution and skin tendering and whitening composition |
| CN105726471A (en) * | 2016-03-16 | 2016-07-06 | 邓学峰 | Medicine composition with vitamin C and method for preparing medicine composition |
-
2019
- 2019-07-31 CN CN201910704274.1A patent/CN110237229A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060216251A1 (en) * | 2005-03-24 | 2006-09-28 | Tracie Martyn International, Llc | Topical formulations and methods of use |
| CN101125126A (en) * | 2006-08-16 | 2008-02-20 | 丛繁滋 | Method for preparing medical freeze-dried powder (injection) preparation |
| JP2010111590A (en) * | 2008-11-04 | 2010-05-20 | Oriza Yuka Kk | Melanogenesis inhibitor |
| US20150342854A1 (en) * | 2012-12-27 | 2015-12-03 | Hayashibara Co., Ltd. | External dermal composition for anti-ageing and method for producing the same |
| CN105535025A (en) * | 2016-01-14 | 2016-05-04 | 无锡瑞博美容咨询服务有限公司 | Skin tendering and whitening nutrient solution and skin tendering and whitening composition |
| CN105726471A (en) * | 2016-03-16 | 2016-07-06 | 邓学峰 | Medicine composition with vitamin C and method for preparing medicine composition |
Non-Patent Citations (1)
| Title |
|---|
| 大山: "美白针配方都是哪些呢 主要介绍两种配方", 《HTTPS://WWW.ZIYIMALL.COM/ZHISHI/38018.HTML》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112386520A (en) * | 2020-11-24 | 2021-02-23 | 西安润玉医疗科技有限公司 | Mesoderm injection composition for comprehensively improving skin color and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sanadi et al. | The effect of Vitamin C on melanin pigmentation–A systematic review | |
| CN110585114B (en) | Bactericidal composition for regulating skin microbial flora and application thereof | |
| CA2558439A1 (en) | Compositions and methods for preventing and treating skin and hair conditions | |
| CA2685321A1 (en) | Solubilized delivery system for topical anesthetics | |
| CN104434707A (en) | Whitening and freckle-removing essence | |
| CN105209051A (en) | Acne solution | |
| US20220183951A1 (en) | Skin treatment methods and compositions with retinoid and delivery systems thereof | |
| CN103347507A (en) | Melatonin and an antimicrobial or antibacterial agent for the treatment of acne | |
| Starkman et al. | Chemical peels: deep, medium, and light | |
| CN110237229A (en) | A kind of pharmaceutical composition of mesotherapy and preparation method thereof for reducing skin pigment and treating pain degree | |
| CN110339084A (en) | A kind of formula and preparation method thereof of the antibacterial essence of polypeptide compound acne-removing | |
| CN112315883B (en) | Skin care composition for controlling oil and removing acne and preparation and application thereof | |
| US20140350106A1 (en) | Urea Silicone Gel for Scars and Hydration Treatment and Method of Using Same | |
| EA006739B1 (en) | Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission | |
| Prager et al. | Treatment of crow’s feet with two different botulinum toxin type: A preparations in split-face technique | |
| CN106511153B (en) | Nanometer composition with acne removing effect and cosmetic or skin care product thereof | |
| CH700735B1 (en) | Biologically active complex, useful e.g. as a cosmetic anti-aging composition, comprises a combination of amino acids, a soy protein hydrolyzate, teprenone and fine Myrtus communis plant extract | |
| Flynn | Periocular botulinum toxin | |
| US20110045096A1 (en) | Solubilized delivery system for topical anesthetics | |
| CN114948805B (en) | Antibacterial composition containing sweet wormwood volatile oil and application of antibacterial composition in acne-removing skin care product | |
| CN111728903B (en) | Injection and cosmetic composition containing lemon balm extract as active ingredient | |
| KR20180097868A (en) | Composition for Cushion Type Foundation Comprising Culture Medium of Houttuynia Cordata Extract | |
| JPH08217659A (en) | Method for decoloring mlanin | |
| Ladha et al. | Soft tissue fillers in skin of color | |
| Yadav et al. | Evaluation of Efficacy and Safety of Botox in the Management of Facial Wrinkles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190917 |
|
| RJ01 | Rejection of invention patent application after publication |